Table 2.
Response summary in Asian patients with ESCC
| Best overall response, n (%) | Pembrolizumab n = 170 | Chemotherapy n = 170 |
|---|---|---|
| ORRa | 29 (17.1) | 12 (7.1) |
| CR | 6 (3.5) | 0 (0) |
| PR | 23 (13.5) | 12 (7.1) |
| SD | 52 (30.6) | 66 (38.8) |
| DCRb | 81 (47.6) | 78 (45.9) |
| PD | 76 (44.7) | 62 (36.5) |
| No assessment/nonassessablec | 13 (7.6) | 30 (17.6) |
CR, complete response; DCR, disease control rate; ESCC, esophageal squamous cell carcinoma; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.
a
CR + PR.
b
CR + PR + SD.
c
Captures patients for whom no post-baseline assessments were carried out because of death, withdrawal of consent, loss to follow-up, or start of new anticancer therapy and patients who had ≥1 post-baseline tumor assessment, none of which were evaluable for response determination (e.g. not all target lesions were captured).